DelMar Pharmaceuticals Inc. is focused on the development and commercialization of proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme, the most common and aggressive form of brain cancer.